Compare HTLD & AVLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HTLD | AVLN |
|---|---|---|
| Founded | 1978 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trucking Freight/Courier Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.3B |
| IPO Year | 1995 | 2026 |
| Metric | HTLD | AVLN |
|---|---|---|
| Price | $12.25 | $35.69 |
| Analyst Decision | Hold | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $11.50 | N/A |
| AVG Volume (30 Days) | ★ 674.8K | 175.5K |
| Earning Date | 04-23-2026 | N/A |
| Dividend Yield | ★ 0.60% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.07 | N/A |
| Revenue | ★ $805,709,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $8.36 | N/A |
| P/E Ratio | $174.71 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $7.00 | $24.90 |
| 52 Week High | $16.64 | $40.17 |
| Indicator | HTLD | AVLN |
|---|---|---|
| Relative Strength Index (RSI) | 43.18 | 52.92 |
| Support Level | $11.75 | $34.22 |
| Resistance Level | $13.09 | $40.08 |
| Average True Range (ATR) | 0.44 | 1.99 |
| MACD | 0.06 | -0.29 |
| Stochastic Oscillator | 39.11 | 35.16 |
Heartland Express Inc, along with its subsidiaries, operates as a short, medium, and long-haul truckload carrier and transportation services provider. It mainly provides nationwide asset-based dry van truckload service for shippers across the United States, along with cross-border freight and other transportation services offered through third-party partnerships in Mexico. The group operates under the brand names of Heartland Express, Millis Transfer, Smith Transport, and CFI (for services within Mexico).
Avalyn Pharma Inc is a clinical-stage biopharmaceutical company developing inhaled medicines to treat rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases (ILDs). Its current pipeline is focused on treating pulmonary fibrosis, a life-threatening disease with a median survival of three to five years, which is a significantly shorter prognosis than that observed for many forms of cancer. Its flagship programs include AP01 and AP02, which are inhaled formulations of pirfenidone and nintedanib being developed for conditions such as progressive pulmonary fibrosis and idiopathic pulmonary fibrosis. The company has one operating and reportable segment, which is the business of developing and commercializing targeted therapies for rare lung diseases.